Oncogenetic Panel and Integrated Clinical Data Registry Study for Wild Type Gastrointestinal Stromal Tumor Patients

Summary

The genetic background for cancer treatment may also be different among different areas and races. There is lack of Taiwanese data of genetic alterations in cancer patients. To understand the landscape of genetic aberrations of cancer in Taiwan, large scale survey of the cancer patients is indicated. In this pilot study, the investigators want to evaluate the landscape of genetic aberrations in cancer patients via oncopaenl test and collect the clinical data of the patients. The result of the oncopanel test will be returned to patient and their attending physician for reference of their further treatment. In addition, the investigators want to correlate the clinical outcome with the genetic aberrations of the cancer patients in Taiwan. Gastrointestinal stromal tumor (GIST) is a rare cancer compared with the other solid tumors. C-KIT or PDGFRA mutation is found in approximately 85-90% of GISTs. Imatinib, a tyrosine kinase inhibitor targeting c-KIT, has been used to treat advanced GIST successfully since 2000. However, resistance to imatinib may develop either via secondary mutation of c-KIT or primary resistance to those with wild type c-KIT and PDGFRA. Although sunitinib and regorafenib have been approved as second and third line of treatment for advanced GIST, the progression free survival were only 6.8 and 4.8 months, respectively. The genetic landscape of GIST with wild type c-KIT and PDGFRA was less studied. In the current study, the investigators want to focus on the GISTs with wild type c-KIT and PDGFRA to perform the NGS oncopanel for these patients. Then the investigators can understand the genetic aberrations of these patients (wild type GIST) and help for searching the potential treatment targets to them.

Conditions

• Gastrointestinal Stromal Tumor (GIST)

Sponsors & Collaborators

• National Taiwan University Hospital

  collaborator OTHER

• Taipei Veterans General Hospital, Taiwan

  collaborator OTHER_GOV

• Tri-Service General Hospital

  collaborator OTHER

• Mackay Memorial Hospital

  collaborator OTHER

• Chang Gung Memorial Hospital

  collaborator OTHER

• China Medical University Hospital

  collaborator OTHER

• Taichung Veterans General Hospital

  collaborator OTHER

• Changhua Christian Hospital

  collaborator OTHER

• Kaohsiung Veterans General Hospital.

  collaborator OTHER

• National Cheng-Kung University Hospital

  collaborator OTHER

• Kaohsiung Medical University Chung-Ho Memorial Hospital

  collaborator OTHER

• Taoyuan General Hospital

  collaborator OTHER_GOV

• National Health Research Institutes, Taiwan

  lead OTHER

Principal Investigators

• Hui-Jen Tsai, M.D. · National Health Research Institutes, Taiwan

• Li-Tzong Chen, Ph.D · [email protected]

Eligibility

Min Age

20 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2021-08-28

Primary Completion

2029-12-31

Completion

2029-12-31

Countries

• Taiwan

Study Locations